www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion Innovations to set up technology transfer unit at Kuwait University
Amphion Innovations PLC (AIM: AMP) said it has signed a partnership agreement with Kuwait University aimed at establishing and operating a technology transfer unit (TTU) at KU. This facility will be the first in-house TTU in Kuwait.
The company will focus on supporting decision making within the TTU on intellectual property (IP) protection. This will include patenting as well as analysing the IP's technical and market value with the key aim of enabling strategic decision making about what, if any, commercialisation efforts are appropriate.
Normally, this commercialisation would take place via licensing, but sometimes it may lead to the creation of a new company. Amphion has already been active for many years in commercialising IP in a number of universities in Europe and the US, it said.
Amphion has an established presence in the region, both through its partner company Motif BioSciences, in which it holds 38.5 percent, and its investor base, which includes members of prominent Gulf families. Motif has been active in the region for over 5 years and has on-going projects looking at the genetic patterns behind major diseases relevant to populations in the Gulf, including diabetes, obesity and some types of cancer.
CEO Richard Morgan said: "As the range of research outputs from Kuwait University continues to grow in scope and international recognition, establishing effective technology transfer functions becomes increasingly important.”
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
Amphion’s other investments include a 19.99 percent stake in Kromek, 20 percent in Myconostica Ltd, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp, 25 percent in Private Markets, 14.6 percent in WellGen and 100 percent in DataTern.
